NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/18/2026 13:57
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization20.92 mln
Float4.19 mln
Earnings Date09/29/2026
Relative Strength
76
/ 100
Strongly outperforming
Debt / Equity
0.00
Debt-free
Pre-Tax Margin
112,785%
Exceptional margin
ROE
-74.73
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Neuphoria Therapeutics Inc. is an Australian clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, with its most advanced drug candidate, BNC210, currently in Phase 2b trials for post-traumatic stress disorder and social anxiety disorder. The company also has oncology assets in its pipeline, including BNC101 and BNC105, alongside earlier-stage programs targeting schizophrenia and autism spectrum disorders. Neuphoria works alongside Merck & Co. to explore treatments for cognitive decline linked to Alzheimer's disease. Formerly known as Bionomics Limited, the company rebranded in December 2024 and is headquartered in Burlington, Massachusetts.
